CVS/pharmacy’s Rob Price named to 2012 Class of Henry Crown fellows
WASHINGTON — Rob Price, CVS/pharmacy’s SVP and chief marketing officer, has been named to the Aspen Institute’s 2012 Class of Henry Crown fellows.
The Henry Crown Fellowship is designed to engage the next generation of leaders in the challenge of community-spirited leadership. It brings together executives from the business world — all entrepreneurs, all younger than 45 years — who have already achieved conspicuous success in their chosen fields and are at a point of inflection in their lives and careers. Previous Henry Crown fellows have included Deval Patrick, governor of Massachusetts; Michael Powell, former Federal Communications Commission chairman; and Reed Hastings, CEO of Netflix.
“Rob represents the type of leader that we believe has the capacity to make a significant impact on our society,” stated Eric Motley, managing director of the Henry Crown Fellowship. “As you can imagine, we are all the more excited to welcome him into the fellowship of 20 other like-minded individuals.”
“Rob’s appointment to the Henry Crown Fellowship for 2012 speaks to the quality of our leadership at CVS Caremark,” stated Larry Merlo, president and CEO of CVS Caremark. “We’re proud of Rob’s selection for this prestigious program, which is focused on community-spirited leadership.”
At CVS/pharmacy, Price is responsible for advertising, promotion, marketing, customer relations and consumer research, as well as retail innovation and store design, the CVS.com e-commerce business and the ExtraCare loyalty program. He also has been instrumental in the integration of the store and digital environments for CVS/pharmacy.
Patents covering Sanctura XR invalid, court rules
PARSIPPANY, N.J. — A court has ruled that patents covering a drug designed to treat an overactive bladder are invalid, a company looking to launch a generic version of the drug said.
Watson Pharmaceuticals said the U.S. District Court for the District of Delaware ruled that five patents covering Allergan’s Sanctura XR (trospium chloride) extended-release capsules were invalid. Watson’s application with the Food and Drug Administration for a generic version are pending, the company said.
Sanctura XR had sales of $68 million during the 12-month period ended in February, according to IMS Health.
Amylin seeks FDA approval for metreleptin
SAN DIEGO — Drug maker Amylin Pharmaceuticals has filed for regulatory approval of a drug to treat diabetes and elevated triglycerides in the bloodstream in children and adults with a rare disorder.
Amylin announced the submission of an application to the Food and Drug Administration for metreleptin in patients with rare forms of lipodystrophy, a life-threatening disorder estimated to affect only a few thousand people around the world. The disease results from the body’s inability to create the hormone leptin, resulting in fat buildup in the blood and organs like the liver and muscles, causing such life-threatening complications as insulin-resistant diabetes, high triglycerides in the blood — also known as hypertriglyceridemia — acute pancreatitis and others.
"Completion of this submission is an important milestone for Amylin and for patients with rare forms of lipodystrophy who currently have limited and often insufficient treatment options for this under-recognized and life-threatening disease," Amylin president and CEO Daniel Bradbury said. "Metreleptin is an integral component of our ongoing commitment to improve the lives of patients with metabolic diseases, from the rarest to the most prevalent."